CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors directed against CTLA-4, PD-1 or PD-L1 have recently demonstrated a therapeutic benefit in various solid tumors (e.g., melanoma, head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, NSCLC, etc.)and lymphoid malignancies (26–31).